Epithelial cancer evaluation using beta defensin
AssigneeCase Western Reserve University
InventorsAaron Weinberg, Santosh Ghosh, Umut A. Gurkan
Life of this patent
Estimating the term…
Abstract
A method of detecting epithelial cancer is described that includes the steps of: (a) determining the level of beta defensin 3 (BD-3) and beta defensin 2 (BD-2) in a suspect sample obtained from a subject; (b) comparing the level of BD-3 to BD-2 determined in the suspect sample to obtain a suspect BD-3/BD-2 ratio, (c) comparing the suspect BD-3/BD-2 ratio to a healthy BD-3/BD-2 ratio to obtain a diagnostic BD-3/BD-2 ratio; and (d) characterizing the subject as having epithelial cancer if the diagnostic BD-3/BD-2 ratio is greater than 1. A microfluidic device for detecting epithelial cancer using the diagnostic BD-3/BD-2 ratio is also described.
Claims13
A system for detection of oral squamous cell carcinoma (OSCC) in a human subject, comprising:
- a microfluidic device comprising a planar substrate comprising a healthy channel and a suspect channel, each channel having an inlet end and an outlet end, and a reagent chamber fluidly connected to both channels, with reagents in the reagent chamber comprising a first labeled binding ligand that specifically binds to human BD-2 (hBD-2), and a second labeled binding ligand that specifically binds to human BD-3 (hBD-3);
- and
- a mobile device configured to access a communications network and having a processor configured to access a camera configured to acquire fluorescent images and used to determine the levels of hBD-3 and hBD-2;
- wherein the mobile device is configured to determine and compare the levels of hBD-3 and hBD-2 to obtain a diagnostic hBD-3/hBD-2 ratio to characterize the subject as having OSCC if the diagnostic hBD-3/hBD-2 ratio is greater than 1.
A system for detection of oral squamous cell carcinoma (OSCC) in a human subject, comprising:
- a microfluidic device;
- and
- a mobile device;
- wherein the microfluidic device comprises a planar substrate comprising a healthy channel and a suspect channel, each channel having an inlet end and an outlet end, and a reagent chamber fluidly connected to both channels, with reagents in the reagent chamber comprising a first labeled binding ligand that specifically binds to human BD-2 (hBD-2), and a second labeled binding ligand that specifically binds to human BD-3 (hBD-3), the healthy channel being configured to determine level of hBD-3 and hBD-2 in a healthy sample, and the suspect channel being configured to determine level of hBD-3 and hBD-2 in a suspect sample obtained from the same subject, and
- wherein the mobile device is configured to access a communications network and has a processor, the processor is configured to access a camera configured to acquire fluorescent images for determining and compare the levels of hBD-3 and hBD-2 to obtain a diagnostic hBD-3/hBD-2 ratio by comparing the suspect hBD-3/hBD-2 ratio to a healthy hBD-3/hBD-2 ratio, and the processor is also configured to characterize the subject as having OSCC if the diagnostic hBD-3/hBD-2 ratio is greater than 1.
Dependencies are inferred from the claim text.